Physician profile
Alejandro Morales
NPI 1134192909
$12,540.04
in general payments reported to CMS, 2019-2025
48 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,824 · 2020: $213 · 2021: $1,049 · 2022: $996 · 2023: $1,366 · 2024: $1,767 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.43 |
| Education | $466.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,274.06 | 2019 | |
| Opko Pharmaceuticals, LLC | $986.33 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $545.25 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $528.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $458.02 | 2019-2025 | Jynarque, Voyxact |
| Daiichi Sankyo INC. | $388.45 | 2022-2025 | Injectafer |
| Amgen INC. | $376.41 | 2022-2025 | Krystexxa, Tavneos, Repatha |
| Astrazeneca Pharmaceuticals Lp | $372.66 | 2019-2025 | Farxiga |
| Outset Medical INC | $296.77 | 2024 | |
| Alexion Pharmaceuticals, INC. | $292.92 | 2020-2024 | Ultomiris |
| Novo Nordisk INC | $254.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $245.60 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $225.07 | 2021-2024 | Livtencity |
| Novartis Pharmaceuticals Corporation | $220.84 | 2021-2025 | |
| Akebia Therapeutics INC | $219.87 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $209.34 | 2020-2024 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $164.25 | 2021-2024 | Lupkynis |
| Scpharmaceuticals INC. | $134.53 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $129.53 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $114.43 | 2022-2024 | Tarpeyo |
| Abbvie INC. | $96.71 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.25 | 2021-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $90.11 | 2022-2024 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $82.10 | 2021 | |
| Penumbra, INC. | $57.08 | 2023 | Indigo System |
| Ascendis Pharma Endocrinology INC | $52.29 | 2024-2025 | Yorvipath |
| Ardelyx, INC. | $48.82 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $45.45 | 2024-2025 | |
| Allergan, INC. | $44.66 | 2019 | |
| Boston Scientific Corporation | $44.39 | 2023-2024 | |
| Genentech USA, INC. | $38.98 | 2019 | |
| Lilly USA, LLC | $35.43 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2023-2024 | Jardiance |
| Cormedix INC. | $35.19 | 2024-2025 | Defencath, Defencath |
| Nxstage Medical, INC. | $32.80 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Genzyme Corporation | $32.25 | 2023 | |
| Acist Medical Systems, INC. | $28.69 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $26.71 | 2023 | Envarsus |
| Cycle Pharmaceuticals INC | $23.28 | 2025 | Venxxiva |
| Astellas Pharma US INC | $22.27 | 2021 | |
| Renalytix Ai, INC. | $20.74 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Abiomed | $19.68 | 2023 | Impella |
| Edwards Lifesciences Corporation | $19.12 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.38 | 2025 | Horizant |
| Apellis Pharmaceuticals, INC. | $17.85 | 2025 | |
| Fresenius USA Marketing, INC. | $15.36 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.84 | 2022 | |
| La Jolla Pharmaceutical Company | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.